🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06493695
Starting soon Not applicable

CES and EGChatbot in Reducing Anxiety, Depression, Insomnia, and Mental Risk

NCT06493695 · tracked via the Priya Life Science China tracker
Sponsor
China Medical University Hospital
Phase
Not applicable
Started
2024-09-30
Last updated
2024-07-10

Condition(s) studied

Depression, Anxiety

Investigational drug(s) / intervention(s)

Both EGChat and CES interventionExercise ChatbotCES (Cranial Electrotherapy Stimulation)

Both EGChat and CES intervention: 1. A exercise-promoting chatbot called EGChat, integrated into an established online health promotion platform. 2. Intervention of CES (Cranial Electrotherapy Stimulation) at Home

Exercise Chatbot: Exercise Chatbot

CES (Cranial Electrotherapy Stimulation): Intervention of CES (Cranial Electrotherapy Stimulation)

Study summary

The objective of this three-year study is to provide comprehensive care to young adults presenting with ARMS. The aim is use an exercise group (EGChat) developed by prior study and CES to decrease cognitive mental risks, improve emotional stability, enhance sleep quality, and elevate overall life satisfaction. A randomized controlled trial (RCT) design will be conducted using purposive sampling to recruit 180 young adults with ARMS from a medical center and its affiliated hospitals. Participants will be randomly assigned to one of three groups, undergoing a 16-week intervention: EGChat plus CES, EGChat without CES, or CES without EGChat groups. The study integrates the EGChat application into an online health promotion platform, coupled with CES intervention, to enhance the biological and psychological health of individuals at ARMS. The goal of this RCT study is to enhance the biological and psychological well-being of individuals with ARMS, covering exercise levels, Brain-Derived Neurotrophic Factor (BDNF) levels, health-promoting behaviors, metabolic indexes, cognitive mental risks, emotional status, sleep quality, and overall life quality. Assessments will occur at baseline (T0), 8 weeks into the intervention (T1), upon completion of the 16-week intervention (T2), and during a follow-up assessment at 3 months post-intervention (T3). The study will utilize generalized estimating equations (GEE) for mixed model repeated measures analysis to evaluate the significant influences of the intervention and interactions between study variables, utilizing group-time interaction.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * between 18 and 65 years old * meet the DSM-5 criteria for ARMS as assessed by psychiatrists, who serve as the Co-PI of this research * exhibit persistent symptoms without clinically significant fluctuations * consent to participate in the study and provide written informed consent. Exclusion Criteria: * have a DSM-5 diagnosis of intellectual disability or substance (including alcohol) use disorder * possess a history of epilepsy, head trauma, central nervous system diseases, or frequent syncope * are pregnant or lactating * have an implanted neurostimulator or cardiac pacemaker * have metal implants in the body * non-removable cochlear implant * are unable to adhere to the protocol (including the absence of a computer, tablet, or smartphone for use)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
China Medical University Taichung Taiwan

More China Medical University Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06493695 on ClinicalTrials.gov ↗ ← All trials in China